Loading…
Jade Biosciences, Inc. is projected to rise to $30.82 by 2027, a +47% move from its current price of $20.95. JBIO is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $20.10 | $20.97 | $21.89 | +0.12% |
| Jul 14 | $19.77 | $21.00 | $22.30 | +0.24% |
| Jul 15 | $19.53 | $21.02 | $22.63 | +0.36% |
| Jul 16 | $19.33 | $21.05 | $22.92 | +0.47% |
| Jul 17 | $19.16 | $21.07 | $23.18 | +0.59% |
| Jul 18 | $19.01 | $21.10 | $23.42 | +0.71% |
| Jul 19 | $18.87 | $21.12 | $23.64 | +0.83% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $18.87 | $21.12 | $23.64 | +0.83% |
| Week 2 | $18.16 | $21.30 | $24.98 | +1.67% |
| Week 3 | $17.67 | $21.48 | $26.11 | +2.52% |
| Week 4 | $17.29 | $21.66 | $27.13 | +3.37% |
| Week 5 | $16.97 | $21.84 | $28.10 | +4.23% |
| Week 6 | $16.71 | $22.02 | $29.02 | +5.10% |
| Week 7 | $16.48 | $22.20 | $29.92 | +5.97% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial.
The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc.
Jade Biosciences, Inc. is based in Waltham, Massachusetts.
Jade Biosciences, Inc. (JBIO) trades at $21.97 per share and has a market cap of $1.34B, ranking 2338 by market capitalization.
The current price and market position set the stage for a forecast that projects rising averages beyond 2026, starting with 2027 avg $31.02 and continuing through 2050 with substantial upside. The forecast shows 2026 avg $21.97, 2027 avg $31.02, 2028 avg $36.09, 2029 avg $40.29, 2030 avg $43.95, 2031 avg $46.26, 2032 avg $70.83, 2033 avg $96.06, 2034 avg $98.16, 2035 avg $110.49, 2040 avg $200.83 and 2050 avg $384.74, with corresponding ROIs.
The implied upside includes max forecasts such as 2032 max $131.39, 2033 max $183.12, 2034 max $191.84, 2035 max $220.93, 2040 max $441.21 and 2050 max $884.89, all signaling bullish potential over the long term.
A major floor 43.0% below — a decisive break under it would weaken the trend.
The nearest floor, 28.5% below — buyers have tended to step in here.
The nearest ceiling, 7.5% above — a clean break opens room to run.
A major ceiling 29.1% above — clearing it would confirm fresh momentum.
Key JBIO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of JBIO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $21.94 | Sell | $21.79 | Sell |
| MA 10 | $21.94 | Sell | $21.54 | Sell |
| MA 20 | $20.06 | Buy | $20.85 | Buy |
| MA 50 | $21.04 | Sell | $20.24 | Buy |
| MA 100 | $18.81 | Buy | $19.16 | Buy |
| MA 200 | $15.65 | Buy | $23.76 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 51.85 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | 24.44 | Neutral |
| Williams %R (14) | -51.30 | Info |
| MACD (12,26,9) | 0.22 | Buy |
| ROC (12) | -4.64 | Sell |
| Bollinger %B (20,2) | 0.58 | Neutral |
| Stochastic %K (14) | 48.70 | Neutral |
| TRIX (15) | 0.31 | Buy |
| Awesome (5,34) | 2.35 | Buy |
| Ultimate (7,14,28) | 46.48 | Neutral |
| Momentum (10) | -0.86 | Sell |
| Aroon Osc (25) | 80.00 | Buy |
| Hull MA (9) | 22.19 | Sell |
| ADX (14) | 23.12 | Buy |
| ATR (14) | 0.65 | Info |
The 30-day technical picture shows a bullish tilt with RSI14 at 60 and overall sentiment labeled BULLISH.
The asset trades around the SMA50 of $21.32, above the SMA200 of $14.78, and the current price is $21.97. A key near-term support sits at $14.98 while resistance is at $25.23, with the 30-day range spanning from $15.21 to $31.73.
Annualized volatility is high at 100%, underscoring the elevated near-term risk and variability in price action.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $13.12 | $20.95 | $32.05 | 0% | Neutral | |
| $23.26 | $30.82 | $43.87 | +47% | Bullish | |
| $24.71 | $34.29 | $51.49 | +64% | Bullish | |
| $27.89 | $40.24 | $62.97 | +92% | Bullish | |
| $31.70 | $47.37 | $76.71 | +126% | Bullish | |
| $31.01 | $47.86 | $79.83 | +128% | Bullish | |
| $43.48 | $69.21 | $118.51 | +230% | Bullish | |
| $57.79 | $94.69 | $166.05 | +352% | Bullish | |
| $57.88 | $97.53 | $174.77 | +366% | Bullish | |
| $64.61 | $111.84 | $204.47 | +434% | Bullish | |
| $100.35 | $197.29 | $391.83 | +842% | Bullish | |
| $186.16 | $413.68 | $924.19 | +18.7x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $13.12 | $20.95 | $25.27 | +0.00% |
| August 2026 | $18.40 | $22.04 | $27.35 | +5.22% |
| September 2026 | $19.26 | $23.34 | $29.46 | +5.88% |
| October 2026 | $18.98 | $23.21 | $29.72 | -0.54% |
| November 2026 | $18.86 | $23.27 | $30.13 | +0.22% |
| December 2026 | $19.70 | $24.48 | $32.05 | +5.22% |
Click any year to see its month-by-month JBIO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect JBIO to range from $13.12 to $32.05 through 2026. The $20.95 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The JBIO price prediction for 2027 points to an average of $30.82 (low $23.26, high $43.87) — a potential gain of +47% on today's $20.95. Momentum favours further upside here.
In 2028, JBIO is projected to trade between $24.71 and $51.49, averaging $34.29 — a potential gain of +64% from today's $20.95. That is up +11% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Jade Biosciences, Inc.'s 2029 outlook centres on $40.24, within a $27.89 to $62.97 range. That is up +17% on the projected 2028 average. That marks a +92% change versus current levels. Momentum favours further upside here.
By 2030, JBIO could reach as high as $76.71, with a base case around $47.37 and support toward $31.70 — roughly +126% from $20.95. Buyers look set to stay in control over this stretch.
Expect JBIO to range from $31.01 to $79.83 through 2031. The $47.86 average target implies a +128% move from current prices. That is up +1% on the projected 2030 average. Momentum favours further upside here.
The JBIO price prediction for 2032 points to an average of $69.21 (low $43.48, high $118.51) — a potential gain of +230% on today's $20.95. Buyers look set to stay in control over this stretch.
In 2033, JBIO is projected to trade between $57.79 and $166.05, averaging $94.69 — a potential gain of +352% from today's $20.95. That is up +37% on the projected 2032 average. Momentum favours further upside here.
Jade Biosciences, Inc.'s 2034 outlook centres on $97.53, within a $57.88 to $174.77 range. That is up +3% on the projected 2033 average. That marks a +366% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, JBIO could reach as high as $204.47, with a base case around $111.84 and support toward $64.61 — roughly +434% from $20.95. Momentum favours further upside here.
Expect JBIO to range from $100.35 to $391.83 through 2040. The $197.29 average target implies a +842% move from current prices. That is up +76% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The JBIO price prediction for 2050 points to an average of $413.68 (low $186.16, high $924.19) — a potential gain of +18.7x on today's $20.95. Momentum favours further upside here.
Investing $1,000 in JBIO today (≈ 47.732697 JBIO) could be worth
$19,745.99
+$18,745.99 (+1875%) by 2050 · US Dollar
Based on the average projected JBIO price of $413.68 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in JBIOwould be worth at today's price.
$1,000 invested in JBIO on Jul 10, 2025 (≈ 95.05703 JBIO) would be worth
$1,991.44
+$991.44 (+99.1%) today · 1.99× · US Dollar
Based on a JBIO entry price of $10.52 vs. today's $20.95.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $21.51 | $973.97 | -2.6% |
| 1 month ago | $15.26 | $1,372.87 | +37.3% |
| 3 months ago | $17.89 | $1,171.05 | +17.1% |
| 6 months ago | $13.86 | $1,511.54 | +51.2% |
| 1 year ago | $10.52 | $1,991.44 | +99.1% |
| All time (5.0y) ago | $557.9 | $37.55 | -96.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our JBIO forecast.
Our base-case forecast reaches $42.00 around 2030.
Implied market cap at $42.00: $2.56B
The multi-year forecast indicates a path of growth with a rising average price from 2027 onward. The 2027 avg is $31.02, rising through 2030 at $43.95 and continuing to 2035 at $110.49, with 2040 at $200.83 and 2050 at $384.74. The corresponding ROIs climb from 41.2 in 2027 to 1651.2 in 2050, and the sentiment remains BULLISH for the long horizon.
Beyond 2030, the forecast shows continued upside with 2032 avg $70.83 and 2033 avg $96.06, followed by 2034 avg $98.16 and 2035 avg $110.49, reflecting a broadening price path. The 2040 and 2050 outlets project even higher averages and Max values, with 2040 max $441.21 and 2050 max $884.89, indicating substantial long-term upside potential alongside rising risk.
These are estimates and not guarantees, and actual results may differ due to factors affecting pharmaceutical development, collaboration dynamics, and market conditions.
Tap a question to reveal the answer.
2030 avg $43.95; min $27.11; max $76.41; ROI 100; sentiment BULLISH.
Forecasts show bullish sentiment in 2027 (avg $31.02) and beyond, with 2030 avg $43.95 and 2050 avg $384.74; ROI climbs to 1651.2 by 2050. These are estimates, not guarantees.
The 2050 max forecast is $884.89.
Current price is $21.97 and market cap is $1.34B; rank 2338.
JADE101 is a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003 in preclinical development, and has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
Jade Biosciences, Inc. Community Discussion
0Share your Jade Biosciences, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.